Evidence map›Paper›PMID 34864125›Full record

ArticleRegulatory toxicology and pharmacology : RTP2022

Safe- and sustainable-by-design: The case of Smart Nanomaterials. A perspective based on a European workshop.

Agnieszka Mech, Stefania Gottardo, Valeria Amenta, Alessia Amodio, Susanne Belz, Søren Bøwadt, Jana Drbohlavová, Lucian Farcal, Paula Jantunen, Aleksandra Małyska and 3 more

Abstract read
In one paragraph

Article in Regulatory toxicology and pharmacology : RTP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Essence of toxicology research to Saudi Arabia Vision 2030 and beyond: Current state and future perspectives.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Safety Assessment of Graphene-Based Materials.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Agnieszka MechEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Stefania GottardoEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Valeria AmentaEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Alessia AmodioEuropean Commission, Directorate-General Research and Innovation (DG RTD), Brussels, Belgium.
Susanne BelzEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Søren BøwadtEuropean Commission, Directorate-General Research and Innovation (DG RTD), Brussels, Belgium.
Jana DrbohlavováEuropean Commission, Directorate-General Research and Innovation (DG RTD), Brussels, Belgium.
Lucian FarcalEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Paula JantunenEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Aleksandra MałyskaEuropean Commission, Directorate-General Research and Innovation (DG RTD), Brussels, Belgium.
Kirsten RasmussenEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Juan Riego SintesEuropean Commission, Joint Research Centre (JRC), Ispra, Italy.
Hubert RauscherEuropean Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic address: hubert.rauscher@ec.europa.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Commission's Green Deal is a major policy initiative aiming to achieve a climate-neutral, zero-pollution, sustainable, circular and inclusive economy, driving both the New Industrial Strategy for Europe and the Chemicals Strategy for Sustainability. Innovative materials can help to reach these policy goals, but they need to be safe and sustainable themselves. Thus, one aim is to shift the development of chemicals to Safe- and Sustainable-by-Design, and define a new systems approach and criteria for sustainability to achieve this. An online workshop was organised in September 2020 by the Joint Research Centre and the Directorate-General Research and Innovation of the European Commission, with participants from academia, non-governmental organisations, industry and regulatory bodies. The aims were to introduce the concept of Safe- and Sustainable-by-Design, to identify industrial and regulatory challenges in achieving safer and more sustainable Smart Nanomaterials as an example of innovative materials, and to deliver recommendations for directions and actions necessary to meet these challenges. The following needs were identified: (i) an agreed terminology, (ii) a common understanding of the principles of Safe- and Sustainable-by-Design, iii) criteria, assessment tools and incentives to achieve a transition from Safe-by-Design to Safe- and Sustainable-by-Design, and (iv) preparedness of regulators and legislation for innovative chemicals/nanomaterials. This paper presents the authors' view on the state of the art as well as the needs for future activities, based on discussions at the workshop and further considerations. The case of Smart Nanomaterials is used to illustrate the Safe- and Sustainable-by-Design concept and challenges for its implementation. Most of the considerations can be extended to other advanced materials and to chemicals and products in general.

Indexed as

EnvironmentGovernment RegulationChemistryEuropean UnionHumansNanostructuresNanotechnologyPolicySustainable DevelopmentEuropean Union policyRegulatory requirementsSafe- and Sustainable-by-DesignSafe-by-DesignSmart nanomaterial

Identifiers

PMID34864125
PMCPMC8795056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.